Form 4: Ligand Pharma CLO Reardon Receives Equity Awards

Ligand Pharmaceuticals' Chief Legal Officer and Secretary, Andrew Reardon, was granted 4,513 restricted stock units and 21,525 employee stock options.

Summary

• Andrew Reardon, Ligand Pharmaceuticals Inc.'s Chief Legal Officer and Secretary, acquired 4,513 shares of common stock in the form of Restricted Stock Units (RSUs) on March 2, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, with a reported price of $0 for the acquisition.
• The RSUs will vest in three substantially equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, contingent on Mr. Reardon's continued service.
• Delivery of shares from the RSU vesting will be deferred pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan.
• Mr. Reardon also acquired 21,525 employee stock options on March 2, 2026, with an exercise price of $202.55 per share.
• The stock options vest and become exercisable as to 12.5% of the underlying shares six months after the grant date, and then in 42 substantially equal monthly installments thereafter.
• The employee stock options have an expiration date of March 2, 2036.
• Following these transactions, Mr. Reardon beneficially owns 41,382 shares of common stock directly and 21,525 derivative securities (employee stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. While it represents potential future dilution, it primarily signifies standard executive compensation designed to align management's long-term interests with shareholder value, which is generally a positive for corporate governance.

Positives

• The equity awards align the interests of the Chief Legal Officer and Secretary, Andrew Reardon, with those of the shareholders, incentivizing long-term performance and retention.
• The deferral of RSU share delivery indicates a commitment to long-term investment in the company by the executive.

Negatives

• The issuance of new equity awards, specifically stock options and RSUs, represents potential future dilution for existing shareholders upon vesting and exercise.

Future Outlook

The future outlook involves the vesting of the granted Restricted Stock Units in three annual installments starting February 15, 2027, and the vesting of employee stock options over a period commencing six months after the grant date and continuing in monthly installments thereafter. The delivery of RSU shares will be deferred according to the company's deferred compensation plan.

Industry Context

StockSavvy.ai notes that the granting of equity awards such as Restricted Stock Units and stock options to key executives is a standard practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to attract, retain, and motivate top talent by linking executive incentives directly to the company's long-term stock performance, thereby aligning management's interests with those of shareholders. This particular filing reflects a routine compensation event for a senior executive at Ligand Pharmaceuticals.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with common practices observed in the U.S. pharmaceutical and biotechnology sectors for executive compensation packages. Companies like Amgen (AMGN), Gilead Sciences (GILD), and Regeneron Pharmaceuticals (REGN) frequently utilize similar long-term incentive plans to retain and motivate their leadership.

Stakeholder Impact

• Shareholders: Potential for minor future dilution from the vesting and exercise of equity awards, but also increased alignment of executive incentives with long-term shareholder value.
• Employees (specifically Andrew Reardon): Enhanced long-term compensation and retention incentives tied to company performance.

Next Steps

• Vesting of 4,513 Restricted Stock Units in three equal annual installments on February 15, 2027, 2028, and 2029.
• Vesting of 21,525 Employee Stock Options, with 12.5% vesting six months after the grant date and the remainder in 42 equal monthly installments.
• Deferred delivery of shares upon RSU vesting as per the Nonqualified Deferred Compensation Plan.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Andrew Reardon, Equity Awards